Not tested in other applications.
*Optimal dilutions/concentrations should be determined by the researcher.
|Predicted Target Size||76 kDa (note)
|Positive Controls||293T , A431 , H1299 , HeLa , HepG2 , Molt-4 , Raji , *Jurkat|
(Please refer to the vial label for the specific concentration)|
|Purification||Purified by antigen-affinity chromatography.|
|Full Name||receptor (TNFRSF)-interacting serine-threonine kinase 1|
|Product Description||Rabbit Polyclonal antibody to RIP (receptor (TNFRSF)-interacting serine-threonine kinase 1)|
|Background||Essential adapter molecule for the activation of NF-kappa-B. Following different upstream signals (binding of inflammatory cytokines, stimulation of pathogen recognition receptors, or DNA damage), particular RIPK1-containing complexes are formed, initiating a limited number of cellular responses. Upon TNFA stimulation RIPK1 is recruited to a TRADD-TRAF complex initiated by TNFR1 trimerization. There, it is ubiquitinated via 'Lys-63'-link chains, inducing its association with the IKK complex, and its activation through NEMO binding of polyubiquitin chains.|
|Synonyms||FLJ39204 antibody, RIP antibody, RIP1 antibody, RIPK1 antibody, cell death protein RIP antibody, receptor-interacting serine/threonine-protein kinase 1 antibody, serine/threonine-protein kinase RIP antibody, receptor-interacting protein 1 antibody, RIP-1 antibody, receptor interacting protein antibody, receptor (TNFRSF)-interacting serine-threonine kinase 1 antibody|
|Immunogen||Recombinant protein encompassing a sequence within the center region of human RIP. The exact sequence is proprietary.|